NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

You argue:

“….And Fipper's more properly stated argument is speculative.

What is a fact is that a "win" in the 232 vs 99 OS comp would be huge, even if not stat sig. It is still an endpoint of the trial. And team NWBO has buried it.” — exwannabe

QALY. If one has a confounded value endpoint, you can win the battle but lose the war, even if the original survival endpoint is significant or strongly trending if QALY is based on it instead of ECA comparison. To obtain reasonable reimbursement, one must unconfound to the most legitimate extent possible. Otherwise, you might get stat. sig., but you can’t get sufficient reimbursement, which would be bad for patients, investors, management and scientific progress.

Right now, reimbursement, calculated from the ECA comparison, will be sufficient.

Right now they don’t want to re-confound by establishing a distorted value calculation by reintroducing the confounded comparison prior to QALY valuation for reimbursement.

To me, it’s all pretty straight forward, and it takes NWBO discipline to keep the horse in front of the cart in this situation, but science and regulatory economics demands it.